



AD-HOC ANNOUNCEMENT ACCORDING TO §15 WPHG

**PAION REPORTS POSITIVE RESULTS OF ITS SHORT ACTING
ANAESTHETIC/SEDATIVE CNS 7056 IN A PHASE IIA STUDY
IN UPPER GI ENDOSCOPY**

- Successfully provides short-term sedation in patients
- Dose dependent efficacy and rapid recovery post sedation
- Good tolerability in all dose groups confirms safety profile

Aachen (Germany), 3 November 2009 – The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today publishes encouraging headline data from the Phase IIA dose finding clinical trial assessing its new ultra short-acting intravenous anaesthetic/sedative CNS 7056 in patients undergoing endoscopy of the upper gastrointestinal tract.

The primary objectives of the trial, which were to further evaluate the safety of CNS 7056, to assess the dose-dependent success of sedation, time to full recovery and discharge in comparison to midazolam (the gold-standard agent), in patients undergoing gastroscopy, were met. The success rate with midazolam was 44 %, with the low dose of CNS 7056 dose 32 %, with the middle dose 56 % and with the highest dose 64 %. This clinically relevant improvement over midazolam has to be confirmed in larger trials, but this study has shown that it is possible to achieve the same or better results as compared to a single dose of the gold standard with a single dose of CNS 7056. The safety profile observed in this trial confirmed the good tolerability also shown in previous data and was anticipated for a benzodiazepine.

Contact

Ralf Penner
Director Investor Relations & Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen – Germany
Phone: +49 241 4453-152
E-mail: r.penner@paion.com
www.paion.com

Disclaimer:

This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments.